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Abstract 
Background: Myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis 
(EAE) is a widely used animal model for multiple sclerosis. The characteristic feature of the MOG-EAE model in Brown 
Norway rats is consistent involvement of the spinal cord resulting in limb paresis. The aim of the study was to inves-
tigate whether early subclinical gait abnormalities are present in this animal model and can be detected by CatWalk 
XT, a fully automated gait analysis system. Furthermore, we investigated the usability of CatWalk system for treatment 
studies.
Results: Our gait analysis showed no preclinical abnormalities in MOG-EAE animals. Nevertheless, we character-
ized a combination of gait parameters that display a high predictive capacity in regard to disease onset. Our detailed 
histopathological analysis of the spinal cord revealed that lesion formation starts in the lumbar region and propagates 
toward the cervical part of the spinal cord during the disease course. In the treatment study, the stabilization of gait 
parameters under the treatment with methylprednisolone was detected in CatWalk as well as in traditional EAE-scor-
ing system.
Conclusions: The results from CatWalk test indicate no benefit of lab-intensive automated gait system in EAE-model 
with chronic-progressive disease course as well as in therapeutic studies with pronounced effect on the severity of 
clinical symptoms. However, due to its quantitative and objective nature this system may display a refined test to 
detect small but functional relevant changes in regeneration-orientated studies.
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Background
Multiple sclerosis (MS) is an autoimmune inflamma-
tory demyelinating disease of the central nervous sys-
tem (CNS). Clinical symptoms of the disease are quite 
heterogeneous. In MS-patients, the expanded disability 
status scale (EDSS) is used to monitor CNS-related dys-
functions [1]. The score is calculated by testing differ-
ent functional systems of the CNS and thereby reflects 
an overall estimation of patient’s disability. Current gait 
analysis in MS-patients with detailed investigation para-
digms revealed that abnormalities in gait occur far earlier 
during the disease course than expected and that these 
subclinical abnormalities are neglected by the EDSS scor-
ing paradigm, especially in the lower range of the scale [2, 
3]. A scoring system similar to EDSS is used for clinical 
evaluation of the CNS-damage in animal models of MS 
[4]. The most commonly used animal model to mimic the 
human disease is experimental autoimmune encepha-
lomyelitis (EAE) [5, 6]. In the present experiments we 
employed an EAE model in Brown Norway (BN) rats. 
Active immunization of BN-rats with myelin oligoden-
drocyte glycoprotein (MOG) leads to the development 
of clinical symptoms within 2  weeks after immuniza-
tion. This animal model displays many of the pathologi-
cal aspects seen in MS-patients [7], with inflammation, 
demyelination and neuronal damage being restricted to 
the spinal cord and optic nerve. The traditional scoring 
Open Access
BMC Neuroscience
*Correspondence:  k.hein@uni-goettingen.de 
4 Department of Neurology, University Hospital, Robert-Koch-Strasse 40, 
37075 Göttingen, Germany
Full list of author information is available at the end of the article
Page 2 of 13Herold et al. BMC Neurosci  (2016) 17:78 
system in EAE ranges from 0 to 4 depends on the severity 
of limbs paresis and therefore reflects spinal cord involve-
ment. Our previous studies on the visual pathway in this 
animal model suggest that treatment with neuroprotec-
tive substances should be started early even in the pre-
clinical stage of the disease [8–10]. Thus, in the present 
project we aimed to evaluate early clinically not detect-
able abnormalities in locomotion using automated gait 
analysis in MOG-immunized animals in order to iden-
tify a specific time point for the start of neuroprotective 
therapies. To that end, we established the CatWalk fully 
automated gait analysis system (CatWalk XT, Noldus 
Information Technology, Netherlands) as a quantitative 
test in MOG-EAE animal model. Furthermore, we inves-
tigated the timeline of histopathological changes in the 
spinal cord in preclinical as well as in clinical stage of the 
disease. Moreover, to investigate the usability of Catwalk 
to detect improvement of locomotion abnormalities we 
applied this automated behavioral test in the treatment 




Forty-two female BN rats in the age of 8–10 weeks were 
used for all experiments. Animals were obtained from 
Charles River (Sulzfeld, Germany) and kept under envi-
ronmentally controlled conditions. Food and drinking 
water was given with free access. All animal experiments 
were controlled by and performed in accordance to the 
local authorities for animal research LAVES (Niedersäch-
sisches Landesamt für Verbraucherschutz und Lebensmit-
telsicherheit, Reg. nr. G13/1332), Oldenburg, Germany.
Immunization, evaluation and treatment of animals
Animals were anesthetized by inhalation of isofluorane 
(Abbott, Wiesbaden; Germany) and injected intrader-
mally at the base of the tail with 200  µl inoculum con-
taining 50  µg recombinant rat MOG (kindly provided 
by C. Stadelmann, Department of Neuropathology, Uni-
versity Medicine Göttingen, Germany) in saline emulsi-
fied with complete Freund’s adjuvant (Sigma-Aldrich, St. 
Louis; MO) containing 200 µg heat-inactivated Mycobac-
terium tuberculosis (strain H37 RA, Difico Laboratories, 
Detroit, MI). Sham-immunized animals received incom-
plete Freund’s adjuvant without MOG. Animals were 
scored for clinical signs of EAE and weighed daily. EAE-
symptoms were scored as follows: 0 no symptoms, 0.5 dis-
tal tail paresis, 1.0 complete tail paralysis, 1.5 complete 
tail paralysis and partial paresis of hindlimbs, 2.0 com-
plete hindlimb paresis on one side, 2.5 complete paresis 
of hindlimbs, 3.0 complete paresis of both hindlimbs 3.5 
complete paresis of hindlimbs and partial paresis of fore-
limbs, 4.0 tetraparesis or death.
In the treatment study, 18 MOG-immunized rats were 
randomly assigned into two different treatment groups 
(9 animals per group). Animals were treated with intra-
peritoneal (i.p.) injections of Mps (20 mg/kg; Urbason®, 
Hoechst Marion Roussel, Frankfurt/Main, Germany) 
or vehicle (0.9% NaCl) on days 1–3 of the disease. To 
exclude interference with the immunization procedure 
two sham-immunized animals were run in parallel.
Locomotion‑data acquisition and analysis
Twenty-four animals were trained prior to recording for 
at least 1  week, meaning that the animals were habitu-
ated to the behavioral testing room and each animal per-
formed at least 3 runs per day. Training was conducted 
by the same person who performed the final experi-
ment and tested the animals. Before recording, animals 
were allowed to habituate and cross the walkway 1–2 
times. Quantitative fully automated gait recording with 
the CatWalk System (CatWalk XT, Noldus Information 
Technology, Netherlands) was performed 1  h before 
immunization and continued from day 4 post immuniza-
tion (4 dpi) onwards until day 12 or 16 dpi depending on 
the severity of EAE-symptoms. Animals had to pass the 
walkway until complete hindlimb paresis was developed 
(corresponding to the clinical score of 3). In the treat-
ment study animals were sacrificed on day 5 of EAE or 
reaching complete paresis with inability to perform suc-
cessful runs in the CatWalk. Therefore, sample size per 
time point differs. Number of animals that successfully 
performed in the CatWalk was: 0 dpi = 24, 4 dpi = 18, 6 
dpi = 15, 8 dpi = 9, 9 dpi = 18, 10 dpi = 15, 11 dpi = 11, 
12 dpi = 8, 12 dpi = 2, 14 and 16 dpi = 1. Time of clini-
cal manifestation differs between animals. The Noldus 
CatWalk system has been described in detail elsewhere 
[11]. In brief, the CatWalk System consists of an enclosed 
walkway (glass plate) that is illuminated by fluorescent 
light. The system is furthermore equipped with a high 
speed color camera connected to a computer with the 
appropriate detection software (CatwalkXT9.1). Ani-
mals were individually placed into the walkway and each 
animal was allowed to move freely in both directions. 
For the detection of all parameters used in the experi-
ments the camera gain was set to 20 and the detection 
threshold to 0.1. All runs with a run duration between 
0.50 and 5.00  s for complete walkway and a maximum 
allowed speed variation of 60% were considered as suc-
cessful runs. For each animal and analyzed time point 3 
compliant runs were acquired per trial. Compliant runs 
were classified for all limbs and statistically analyzed. The 
software is able to detect several dynamic parameters of 
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an animal’s walk. In the present study parameters that are 
linked to coordination and balance were predominantly 
analyzed (Fig.  1). Paw statistics were not included into 
the analysis. Stride length gives the distance between one 
limb touching the glass blade in one step cycle and touch-
ing the plate again in the next. Base of support is the 
distance of both forelimbs or of both hindlimbs to each 
other indicating the inclination of legs. The footprint pat-
tern illustrates the composition of one step cycle. Under 
normal conditions the used pattern in rodents can differ 
because of disease or stress conditions [11]. The pres-
sure which is given to each paw is calculated by foot print 
intensity and partially by the area which is covered by the 
footprint. These parameters and further dynamic param-
eters like run duration or swing speed were statistically 
analyzed. All these parameters were statistically quanti-
fied for all time points investigated.
Histopathology and Immunohistochemistry
Three individual animals were sacrificed for each time 
point. Histopathological evaluation of spinal cord was 
performed on paraformaldehyde-fixed paraffin-embed-
ded 2 µm sections. Spinal cord was divided in a cervical, 
thoracic and lumbar region. Subsequently, we subdivided 
the cervical part in 3 tissue blocks, the thoracic region in 
6–8 small tissue blocks and the lumbar part in 3–4 tissue 
blocks. The number of tissue blocks from each anatomi-
cal region varies. Finally, cervical, thoracic and lumbar 
tissue blocks were embedded in a standardized sequence 
in one paraffin block each. Thus, this technique ena-
bles us to evaluate a greater surface area of anatomical 
regions. Luxol Fast Blue staining was performed to assess 
demyelination. Staining procedure is described in detail 
elsewhere [9]. Immunohistochemistry was performed on 
adjacent paraffin sections. ED-1 positive macrophages/
activated microglia (MCA341R, Biorad AbD Sero-
tec GmbH, Puchheim, Germany; diluted 1:500), CD-3 
positive T-lymphocytes (BZL03543, Biozol Diagnostica 
GmbH, Eching, Germany; diluted 1:100) and β-amyloid 
precursor protein (APP) positive axons (MAB348, 
Chemicon, Ford, UK; diluted 1:1000) as a marker for 
acute axonal damage were stained in all tissue sections. 
Anti-rabbit-biotinylated antibody was used as a second-
ary antibody. Spleen sections served as positive control 
for ED1 staining.
Microscopic techniques and evaluation of staining
Images of spinal cord sections were taken with Olympus 
dot Slide 2.1 system, based on the upright BX51 micro-
scope and a high resolution color camera (Olympus 
Fig. 1 Dynamic parameters for gait analysis in BN-rats. a Section from original footprints recorded from a healthy BN-rat. The animal is running to 
the right. b Normal step-pattern in healthy BN-rats is quite constant and usually gives a regularity index of almost 100%. c Mean footprint intensity 
from all four limbs is comparable under healthy conditions. RF right forelimb, RH right hindlimb, LF left forelimb, LH left hindlimb, BOS base of sup-
port
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Deutschland GmbH, Hamburg, Germany). Mosaic-
Images of complete spinal cord cross sections were taken 
with 20×  objective. For each anatomic position within 
the optic nerve or spinal cord at least 3 individual sec-
tions were imaged.
Evaluation of demyelination was measured as previ-
ously described [7, 12]. The evaluation of ED1 positive 
cells was performed using the following score: (0) no 
labelled cells; (1) a few ED1 positive cells (number count-
able) in at least one of the three cross sections of the spi-
nal cord; (2) infiltration of less than 10% of the ON cross 
section area with ED1 positive cells (number not counta-
ble) in at least one of the three cross sections of the spinal 
cord; (3) infiltration of 10–50% of the spinal cord cross 
section area with labelled ED1 positive cells in at least 
one of the three cross sections of the spinal cord; (4) infil-
tration of 80% of the cross section area; (5) infiltration of 
more than 80% of the cross section area in at least one 
of the three cross sections of the spinal cord. The num-
ber of CD3-positive cells and β-APP positive axons was 
counted in three different spinal cord sections per region.
Statistical methods
The distribution of each study parameter was described 
by its mean  ±  standard deviation, separately for each 
time after immunization. The mean time courses 
(±standard deviation) were plotted for each parameter. 
The effect of time and group as well as their interaction 
was assessed by analysis of variance for longitudinal data, 
i.e. by repeated measures ANOVA. Group effects were 
further studied at each time by means of t tests. Before-
hand, the normality of each parameter was checked by 
normal quantile–quantile plots. The significance level 
for the analysis of variance models was set to α  =  5%. 
In the case of a significant global group effect, t tests 
were also performed at a significance level of 5%, and at 
Bonferroni–Holm adjusted levels otherwise. The effect 
of elapsed time and all other study parameters of the dis-
ease status of the animals were assessed by univariate and 
multivariate logistic regression for clustered data to take 
the repeated measures situation into account.
All analyses were performed using the statistic software 
R (www.r-project.org), the analysis of variance and logis-
tic regression was modelled by means of generalized esti-
mating equation using the R-package ‘geepack’.
The datasets supporting the conclusions of this article 
are included within the article.
Results
Assessment of locomotion in preclinical and clinical EAE
After immunization, animals were scored for clinical signs 
of EAE and weighed daily. As expected sham-immunized 
animals gained weight and did not display any disabilities 
during observation period whereas MOG-immunized ani-
mals lost weight at the time of clinical manifestation of EAE 
(Fig. 2). The time of disease onset in MOG-immunized ani-
mals was at day 11.3 ± 0.82 post immunization in the first 
part of the experiment. Because weight loss did not excess 
more than 10% of total body weight in any animal this phe-
nomenon does not interfere with gait recording.
As mentioned above the aim of the study was to quan-
tify early, in regard to the EAE scoring paradigm sub-
clinical abnormalities in the gait of MOG-EAE animals 
compared to sham-immunized control animals. There-
fore, we quantified statistically a great cohort of run-
parameters in sham- and MOG-immunized animals.
A significant group-effect (P  <  0.001) was detected 
for the parameter run duration whereas neither time 
nor interaction of time and group revealed significant 
impact (P  =  0.069 for time and P  =  0.349 for group-
by-time interaction) (Fig.  3). Analysis of base of sup-
port (BOS) of fore- and hind-limbs did not reveal any 
Fig. 2 Weight (a) and EAE-score (b) curves of sham- and MOG-immunized animals. Sham-immunized healthy animals gained weight during the 
experiment and did not develop clinical signs of EAE. MOG-immunized animals slightly lost weight at EAE onset
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significant differences in time (P  =  0.241 for forelimbs 
and P  =  0.473 for hindlimbs) or group (P  =  0.795 for 
forelimbs and P = 0.051 for hindlimbs) or the interaction 
of time and group (P = 0.444 for forelimbs and P = 0.491 
for hindlimbs; Fig. 3).
In addition, the straight length of hindlimbs and fore-
limbs as well as the swing speed of fore- and hind-limbs 
were quantified. Based on EAE-scoring paradigm these 
gait-parameters appeared to be highly affected at clini-
cal manifestation of EAE. A significant difference between 
MOG and sham animals was detected for stride length and 
swing speed at time point 4 for the left forelimbs as well as 
hindlimbs (Table 1). This is due to overall higher values in 
the control group compared to the MOG group (Fig. 4).
Besides these parameters we quantified: print area, 
maximal intensity of footprints, maximal contact area, 
step sequence number of patterns and step sequence 
Regularity index of all four limbs.
Predictive power of gait‑analysis during disease induction 
is restricted to the right‑sided extremities
Logistic regression yielded that the strongest predic-
tive power with regard to the disease status of the ani-
mals was given by the parameters run duration, average 
of stride length (front right) and the average of stride 
length (back right). Their predictive power was also dem-
onstrated in ROC curve analyses yielding area under the 
curve (AUC) values between 0.75 (run duration), 0.81 
(average of stride length, front right) and 0.83 (average of 
stride length, back right) (Fig. 5).
Taking together the data validated that there is no 
single gait-parameter which can be used as a predictive 
marker. Although all of the gait parameters shown above 
have a high predictive power, they are only useful if they 
are analyzed together to gain a reliable tool for prediction 
of disease onset.
Histopathological changes in the spinal cord
For each time point three animals were sacrificed and the 
spinal cord was taken out for histopathological analysis. 
No obvious histopathological changes in the spinal cord 
were observed before clinical manifestation of the dis-
ease. The inflammatory lesions were characterized by an 
infiltration of macrophages. Quantification of CD3-posi-
tive cells revealed that only a minority of infiltrating cells 
were CD3 + T-lymphocytes (13.6 ± 4.72; 56.33 ± 11.02; 
105.5 ± 16.21 cells per section at day 11 dpi, 12 dpi and 
14 dpi respectively). Within the lesions, myelin was lost 
and the extent of inflammation was consistent with the 
degree of inflammation (Fig.  7). Demyelinating lesions 
were typically located around submeningeal veins and 
relatively large vessels rather than in parenchymal vessels 
and underlying grey matter. Immunohistochemistry for 
Fig. 3 Comparison of run duration and inclination of legs. a run 
duration time is overall higher in the MOG-immunized than in the 
control group. Base of support (BOS) of forelimbs (b) as well as BOS 
of hindlimbs (c) were unchanged in preclinical and clinical EAE com-
pared to control animals
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beta APP indicated acute axonal damage starts at disease 
onset (116.44 ± 70.64/section for 11 dpi) and increased 
during the disease course (298.66  ±  186.71/section 
for 12 dpi and 304.56  ±  41.44/section  14 dpi respec-
tively). Analysis of the different regions of the spinal 
cord revealed that lesion formation starts in the lumbar 
region of the spinal cord at the day of clinical manifesta-
tion of EAE and propagate toward the cervical portion of 
the spinal cord during the disease course (Fig. 6). Before 
the onset of first clinical symptoms we found no histo-
pathological abnormalities in the spinal cords for all time 
points analyzed.
Evaluation of clinical parameters during the steroid 
treatment
To further investigate the usability of fully automated 
locomotion assessment in therapeutic studies we investi-
gated gait behaviour of MOG-immunized animals under 
the treatment with Mps, a standardized treatment for 
MS. The treatment of animals was started at the day of 
clinical manifestation of EAE and continued for 3 con-
stitutive days with a dose of 20  mg/kg. Animals were 
clinically followed until day 5 of EAE. The day of dis-
ease manifestation did not significantly differ between 
the groups. Vehicle-treated animals developed symp-
toms at day 11.67 ± 0.87 (n = 9) post immunization. In 
Table 1 Table representing the significantly different parameters between  MOG-immunized and  control group at  the 
specific time point
Side Parameter Time Control Treatment P p.Holm
Left BackMaxContactArea_cm2_Mean 9 0.98 ± 0.07 0.72 ± 0.17 0.0024 0.0144
Left BackMaxIntensity_Mean 9 193.69 ± 8.71 166.56 ± 22.74 0.0062 0.0372
Left BackPrintArea_cm2_Mean 8 1.67 ± 0.14 1.11 ± 0.37 0.0038 0.0204
Left BackPrintArea_cm2_Mean 9 1.35 ± 0.11 0.96 ± 0.28 0.0034 0.0204
Left BackStrideLength_cm_Mean 4 13.74 ± 0.32 12.67 ± 0.97 0.0035 0.0245
Left BackSwing_s_Mean 4 0.13 ± 0 0.15 ± 0.02 0.001 0.006
Left BackSwingSpeed_cm.s_Mean 4 108.29 ± 4.51 89.21 ± 14.17 9e−04 0.0063
Left FrontMaxContactArea_cm2_Mean 10 1.44 ± 0.1 1.08 ± 0.22 0.004 0.024
Left FrontMaxIntensity_Mean 4 200.38 ± 3.35 186.52 ± 20.48 0.0097 0.046
Left FrontMaxIntensity_Mean 8 195.44 ± 10.15 163.39 ± 22.45 0.0092 0.046
Left FrontMaxIntensity_Mean 10 203.06 ± 2.04 172.51 ± 24.26 4e−04 0.0024
Left FrontMaxIntensity_Mean 12 204.88 ± 7.67 169.93 ± 28.29 0.0112 0.046
Left FrontPrintArea_cm2_Mean 10 1.66 ± 0.12 1.28 ± 0.19 0.008 0.04
Left FrontPrintArea_cm2_Mean 11 1.94 ± 0.16 1.42 ± 0.4 0.0066 0.0396
Left FrontStrideLength_cm_Mean 4 14.08 ± 0.47 12.56 ± 1.3 0.0047 0.0376
Left FrontSwingSpeed_cm.s_Mean 4 97.23 ± 3.82 81.76 ± 14.98 0.0016 0.0128
Right BackMaxContactArea_cm2_Mean 8 1.29 ± 0.11 0.78 ± 0.28 0.0012 0.0072
Right BackMaxContactArea_cm2_Mean 9 0.95 ± 0.05 0.72 ± 0.29 0.0071 0.0284
Right BackMaxContactArea_cm2_Mean 11 1.39 ± 0.18 0.74 ± 0.35 0.0033 0.0165
Right BackPrintArea_cm2_Mean 8 1.72 ± 0.12 1.06 ± 0.38 0.001 0.005
Right BackPrintArea_cm2_Mean 9 1.32 ± 0.08 0.97 ± 0.41 0.0041 0.0164
Right BackPrintArea_cm2_Mean 11 1.95 ± 0.13 1.02 ± 0.47 2e−04 0.0012
Right FrontMaxContactArea_cm2_Mean 8 1.63 ± 0.04 0.94 ± 0.32 2e−04 0.0012
Right FrontMaxContactArea_cm2_Mean 9 1.45 ± 0.11 1.12 ± 0.28 0.0085 0.034
Right FrontMaxContactArea_cm2_Mean 11 1.78 ± 0.1 1.23 ± 0.4 0.0012 0.006
Right FrontMaxIntensity_Mean 8 205.75 ± 1.47 152.01 ± 36.72 0.0023 0.0138
Right FrontMaxIntensity_Mean 10 197.77 ± 8.23 167.24 ± 30.55 0.0064 0.032
Right FrontMaxIntensity_Mean 11 206.04 ± 1.86 173.16 ± 35.76 0.0123 0.0492
Right FrontPrintArea_cm2_Mean 8 1.84 ± 0.08 1.15 ± 0.33 2e−04 0.0012
Right FrontPrintArea_cm2_Mean 9 1.63 ± 0.09 1.31 ± 0.29 0.0041 0.0164
Right FrontPrintArea_cm2_Mean 11 2.08 ± 0.15 1.45 ± 0.39 0.0019 0.0095
Right FrontSwing_s_Mean 4 0.14 ± 0.01 0.17 ± 0.03 0.0082 0.0492
Right StepSequence_RegularityIndex_percent 4 99.47 ± 0.92 95.94 ± 3.9 0.003 0.018
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Fig. 4 Time-specific comparison of dynamic gait parameter in MOG-versus sham-immunized animals
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the Mps-treated animals first neurological symptoms 
occurred at day 11.86 ± 1.12 (n = 9) post immunization. 
Also the severity of symptoms at disease manifestation 
did not differ significantly in the different groups (vehi-
cle: 2.63 ±  0.52, Mps: 1.44 ±  0.81, P =  0.006) although 
the tendency to the less severity was observed in Mps-
treated animals. In contrast to the control group, move-
ment disturbances were stabilised in the animal group 
treated with Mps (Fig. 8). Therefore, gait-recording could 
be successfully performed until day 1 or day 2 of EAE in 
control and until day 5 of EAE in Mps-treated animals.
Additionally to the classical EAE score, CatWalk analy-
sis was performed in Mps-treated animals and controls. 
The analysis revealed that all gait parameters (rundura-
tion, BOS of hindlimbs or forelimbs, swing speed and 
stride length) are significantly different between the two 
experimental groups with better performance in Mps-
treated animals (Table 2).
Discussion
CatWalk XT gait analysis system provides the possibil-
ity to quantify changes in locomotion of an animal in a 
highly precise and fully automated way. We analysed a 
cohort of different dynamic gait parameter in preclinical 
as well as during the clinical phase of EAE. In this study, 
we addressed the questions whether early subclinical gait 
alterations can be detected before overt locomotor dys-
function detected by the standardized EAE score and 
whether the CatWalk system can be served as a refined 
behavioral testing for treatment studies. Furthermore, 
we investigated the timeline for the histopathological 
changes occurring in the spinal cord in MOG-EAE in 
BN-rats. The investigation of the different gait param-
eters did not reveal any abnormalities in the preclinical 
phase of EAE. Analysing the predictive power of gait 
parameters in regard to disease onset in this model, we 
detected that the average of run duration, the average of 
stride length back right and the average of straight length 
front right displayed the highest predictive power for the 
disease onset. The reason for the involvement of the right 
side is not known. Histopathological analysis revealed 
that pathological changes in the spinal cord occur simul-
taneously with the behavioral abnormalities.
Classically the CatWalk was developed to quantify 
axonal regeneration in rat animal models of traumatic 
spinal cord injury [11, 13]. In contrast, the application 
of the behavioral tests in conventional EAE models is 
limited due to the disseminated and variable nature of 
the disease makes a correlation of clinical deficits and 
defined tract system very complex and often impossible. 
In the MOG-EAE model used in this study the lesions 
are restricted to the spinal cord and optic nerve renders 
this model suitable for automated behavioral testing. 
In the same animal model apoptosis of retinal ganglion 
cells with decline of visual function in electrophysiologi-
cal recordings was observed in the preclinical phase of 
EAE. At this time point no histopathological abnormali-
ties were detected in the optic nerve [12, 14]. In MOG-
EAE model in mice axonal loss in the spinal cord was 
detected before clinical manifestation of the disease 
[15]. However, it is not clear whether the abnormali-
ties observed by histopathology and electrophysiology 
leads to the clinical signs detectable in more sophisti-
cated behavioral test. Therefore, in the present study, we 
aimed to detect gait abnormalities by automated Cat-
Walk system before overt clinical signs in conventional 
EAE-score. The analysis of the gait parameters did not 
show any preclinical abnormalities by using automated 
behaviour test. Similar to our previous study on the optic 
nerve [12], we found no histopathological abnormali-
ties (inflammatory infiltration and demyelination) in the 
spinal cord before the manifestation of the disease. In 
our study, histopathological analysis of the spinal cord 
showed first signs of inflammation and demyelination at 
Fig. 5 ROC curves of parameters in the MOG-EAE group
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the day of clinical manifestation of EAE. Acute axonal 
damage was also first present at this time point. These 
alterations occur with caudal-rostral gradient. In the later 
disease stages of clinical manifest EAE we detected that 
the thoracic and the cervical regions of the spinal cord 
are increasingly affected by the disease. Based on the 
Fig. 6 Histopathology of the spinal cord of sham-immunized and MOG-immunized animals. Inflammation (ED1) as well as demyelination start in 
the lumbar part of the spinal cord and propagates toward the cervical area. There are no histopathological changes detectable in the preclinical 
phase of EAE. Circles represent values for one individual animal
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anatomical organization of innervation of the limbs this 
histopathological alteration correlates well with partial 
paresis or weakness of hindlimbs at the disease onset and 
involvement of the forelimbs during the disease course 
[16]. Our histopathological data of inflammation, demy-
elination and axonal damage of the spinal cord are not 
Fig. 7 Spinal cord (SC) histopathology. Representative examples of ED1-staining in animal at 4 days post immunization (dpi) shows no abnormali-
ties (a); small level of inflammatory infiltration at 11d pi (b); in contrast heavily infiltrated SC section at 14 dpi (c). Representative Luxol Fast Blue-
stained cross-section of the SC shows intact myelin (blue) in animal at 4 dpi (d) only small areas of demyelination, with mainly intact myelin (blue) on 
11 dpi (e); a cross-section from diseased animal on day 14 dpi (f) shows extensively demyelinated areas (purple)
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surprising and are in line with histopathological evidence 
of close association of inflammation and neurodegenera-
tion at all stages of MS [17].
There are several tentative explanations why we failed 
to observe preclinical abnormalities by CatWalk system. 
One obvious possibility would be that the symptoms 
are not present at these early investigation time points. 
However, also the limitations of the automated test 
as well as of the used EAE-model should be taken into 
account. CatWalk gait system belongs to the category 
of unforced type of locomotion analysis, in which the 
animal is free to move at any velocity [18]. Thus, while 
mimics natural locomotion behaviour more closely this 
system is not able to ensure the animal to move exactly 
at the same speed. Also intraindividual and interindivid-
ual variability have been reported when using unforced 
systems in normal rodents [19, 20]. Therefore, speed 
related alterations could be superimposed and thereby 
invisible in the statistical analysis. In comparison, in 
another EAE-model improvement of motor coordina-
tion was only apparent in a speed controlled rotarod test 
and could not be detected by using the traditional scor-
ing system [21]. Experimental model used in our study 
is relatively heterogeneous in the time point of clini-
cal manifestation of EAE and the severity of symptoms 
at disease onset. Moreover, moderate to severe deficits 
occurred during the disease course prevented animals to 
perform CatWalk test. Furthermore, despite the consist-
ent involvement of the spinal cord in this animal model 
we found that the pathology is randomly distributed and 
is not restricted to the specific motor tract system. In 
our study, disseminated lesions were detected in dorsal, 
lateral and ventral funiculi contributing to the diversity 
of symptoms at the disease onset. In contrast, the behav-
ioral testing could be successfully applied in localized 
EAE model specifically targeting dorsal column of the 
spinal cord [22].
In aforementioned EAE-studies demonstrating benefit 
of behavioral test for analysing motor function deficits 
[21, 22]. EAE course was either monophasic with rapid 
recovery or relapsing-remitting making the measure-
ments of improvement with behavioral tests possible. 
In contrast, the disease course of MOG-EAE in BN rats 
is monophasic with continued worsening of the symp-
toms. Therefore, to assess whether CatWalk analysis 
can be used as a test for recovery, animals were treated 
with Mps, a standard relapse therapy in MS. Assess-
ment of locomotion in diseased MOG-EAE-animals 
revealed clinical stabilization of the gait parameters after 
Mps treatment was initiated. This data of manipula-
tion on the immune response with cortisone treatment 
support hypothesis that inflammation is the principle 
determinate of reversible neurological disability in an 
early phase of the disease. However, substantially better 
performance in CatWalk of animals under Mps treat-
ment was also mirrored in the conventional EAE-scoring 
paradigm.
Conclusions
Overall, despite being objective test, the results from 
CatWalk test obtained during the disease course reflect 
the far less labor-intensive routinely used EAE score. Our 
results of no detectable preclinical gait abnormalities and 
stabilisation of symptoms after initiation of therapy indi-
cate that CatWalk analysis can be used in repair-oriented 
rather than in neuroprotective treatment studies since 
neuroprotective treatment should be applied before the 
manifestation of the disease as have been shown previ-
ously in this particular animal model [8, 9, 23]. Being 
quantitative test CatWalk assessment may provide more 
Fig. 8 Weight (a) and clinical score (b) of MOG-immunized Mps- or sham-treated and sham-immunized healthy control animals
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sensitive information of locomotion changes in regenera-
tion studies and therefore “unmask” functional improve-
ment not visible in the traditional EAE-scoring paradigm. 
However, CatWalk analysis should be combined with 
histopathological and electrophysiological studies to give 
a more accurate view of structure–function relations of 
disease processes in EAE.
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